Nanobiotix: 5th ongoing trial in collaboration with MD Anderson

(Boursier.com) — A first patient received an injection of NBTXR3 as part of a Phase 1/2 study evaluating NBTXR3 activated by radiotherapy in combination with anti-PD-1/L-1 immune checkpoint inhibitors in patients with advanced solid tumors associated with lung metastases and/or liver metastases. The trial (NCT05039632) is being conducted as part of the strategic collaboration between Nanobiotix and the University of Texas MD Anderson Cancer Center, which is evaluating radiotherapy-activated NBTXR3 in different solid tumor indications and in combination with different anti-cancer agents.

This new study led by MD Anderson therefore extends the strategic collaboration to five trials currently recruiting.